Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study

被引：0

作者：

Piedra, A. ^{[1
]}

Recio, S. Martinez ^{[1
]}

Gonzalez, A. Hernandez ^{[2
]}

Bueno, M. T. Moran ^{[2
]}

Arriola, E. ^{[3
]}

Recuero-Borau, J. ^{[4
]}

Dols, M. Cobo ^{[5
]}

Gonzalez, P. Cordeiro ^{[6
]}

Martinez, J. Mosquera ^{[7
]}

Garcia-Campelo, M. R. ^{[7
]}

Blanco, A. Calles ^{[8
]}

Alvarez, R. M. ^{[8
]}

Garcia, M. Zapata ^{[9
]}

Casado, M. D. Isla ^{[9
]}

Perez, A. Callejo ^{[10
]}

Gomez, P. Iranzo ^{[10
]}

Joaquin, A. Barba ^{[1
]}

Sullivan, I. G. ^{[1
]}

Felip, E. ^{[11
]}

Majem, M. ^{[1
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[2] Hosp Badalona Germans Trias & Pujol, Dept Med Oncol, ICO Inst Catala Oncol Badalona, Badalona, Spain

[3] Hosp Mar CIBERONC, Dept Med Oncol, Barcelona, Spain

[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain

[5] Hosp Reg Univ Malaga Carlos Haya, Dept Med Oncol, Malaga, Spain

[6] Inst Invest Biomed Coruna INIBIC, Dept Med Oncol, La Coruna, Spain

[7] CHUAC Complexo Hosp Univ A Coruna, Dept Med Oncol, La Coruna, Spain

[8] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain

[9] Hosp Clin Univ Lozano Blesa, Dept Med Oncol, Zaragoza, Spain

[10] Vall Hebron Univ Hosp VHIO, Dept Med Oncol, Barcelona, Spain

[11] Vall Hebron Univ Hosp VHIO, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2507

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1476P

引用

页数：2

共 50 条

[31] Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression (HOT/NJLCG2001 secondary report)
Tateishi, Kazunari
Mizugaki, Hidenori
Ikezawa, Yasuyuki
Morita, Ryo
Yokoo, Keiki
Sumi, Toshiyuki
Kikuchi, Hajime
Kitamura, Yasuo
Nakamura, Atsushi
Kobayashi, Maki
Aso, Mari
Kimura, Nozomu
Yoshiike, Fumiaki
Furuta, Megumi
Tanaka, Hisashi
Sekikawa, Motoki
Hashiya, Tsutomu
Fujita, Yuka
Oizumi, Satoshi
ANNALS OF ONCOLOGY, 2023, 34 : S1394 - S1394
[32] PD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy
Hong, Nicky Wong Zhun
Zhao, Joseph J.
Zhu, Ke Xin
Yap, Dominic Wei Ting
Kumarakulasinghe, Nesaretnam Barr
Huang, Yiqing
Sundar, Raghav
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[33] Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
Cortellini, Alessio
Cannita, Katia
Tiseo, Marcello
Cortinovis, Diego L.
Aerts, Joachim G. J., V
Baldessari, Cinzia
Giusti, Raffaele
Ferrara, Miriam G.
D'Argento, Ettore
Grossi, Francesco
Guida, Annalisa
Berardi, Rossana
Morabito, Alessandro
Genova, Carlo
Antonuzzo, Lorenzo
Mazzoni, Francesca
De Toma, Alessandro
Signorelli, Diego
Gelibter, Alain
Targato, Giada
Rastelli, Francesca
Chiari, Rita
Rocco, Danilo
Gori, Stefania
De Tursi, Michele
Mansueto, Giovanni
Zoratto, Federica
Filetti, Marco
Bracarda, Sergio
Citarella, Fabrizio
Russano, Marco
Cantini, Luca
Nigro, Olga
Buti, Sebastiano
Minuti, Gabriele
Landi, Lorenza
Ricciardi, Serena
Migliorino, Maria R.
Natalizio, Salvatore
Simona, Carnio
De Filippis, Marco
Metro, Giulio
Adamo, Vincenzo
Russo, Alessandro
Spinelli, Gian P.
Di Maio, Massimo
Banna, Giuseppe L.
Friedlaender, Alex
Addeo, Alfredo
Pinato, David J.
EUROPEAN JOURNAL OF CANCER, 2021, 148 : 24 - 35
[34] Re: Post-progression outcomes of NSCLC patients with PD-L1 expression ≥50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
Sutcuoglu, Osman
ozdemir, Nuriye
Yazici, Ozan
EUROPEAN JOURNAL OF CANCER, 2021, 155 : 294 - 295
[35] PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 < 50%: a multiomics analysis
Lo Russo, Giuseppe
Prelaj, Arsela
Dolezal, James
Beninato, Teresa
Agnelli, Luca
Triulzi, Tiziana
Fabbri, Alessandra
Lorenzini, Daniele
Ferrara, Roberto
Brambilla, Marta
Occhipinti, Mario
Mazzeo, Laura
Provenzano, Leonardo
Spagnoletti, Andrea
Viscardi, Giuseppe
Sgambelluri, Francesco
Brich, Silvia
Miskovic, Vanja
Pedrocchi, Alessandra Laura Giulia
Trovo, Francesco
Manglaviti, Sara
Giani, Claudia
Ambrosini, Paolo
Leporati, Rita
Franza, Andrea
McCulloch, John
Torelli, Tommaso
Anichini, Andrea
Mortarini, Roberta
Trinchieri, Giorgio
Pruneri, Giancarlo
Torri, Valter
De Braud, Filippo
Proto, Claudia
Ganzinelli, Monica
Garassino, Marina Chiara
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)
[36] Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
Marmarelis, M. E.
Mathew, D.
Bauml, J. M.
Hwang, W. -T.
Zhang, J.
Singh, A.
D'Avella, C.
Davis, C.
Ye, D.
Sun, L.
Ciunci, C.
Zhang, N.
Aggarwal, C.
Cohen, R. B.
Minn, A. J.
Wherry, E. J.
Langer, C. J.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S122 - S123
[37] Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
Cortellini, Alessio
Ricciuti, Biagio
Tiseo, Marcello
Bria, Emilio
Banna, Giuseppe L.
Aerts, Joachim G. J., V
Barbieri, Fausto
Giusti, Raffaele
Cortinovis, Diego L.
Migliorino, Maria R.
Catino, Annamaria
Passiglia, Francesco
Torniai, Mariangela
Morabito, Alessandro
Genova, Carlo
Mazzoni, Francesca
Di Noia, Vincenzo
Signorelli, Diego
Gelibter, Alain
Occhipinti, Mario Alberto
Rastelli, Francesca
Chiari, Rita
Rocco, Danilo
Inno, Alessandro
De Tursi, Michele
Di Marino, Pietro
Mansueto, Giovanni
Zoratto, Federica
Grossi, Francesco
Filetti, Marco
Pizzutilo, Pamela
Russano, Marco
Citarella, Fabrizio
Cantini, Luca
Targato, Giada
Nigro, Olga
Ferrara, Miriam G.
Buti, Sebastiano
Scodes, Simona
Landi, Lorenza
Guaitoli, Giorgia
Della Gravara, Luigi
Tabbo, Fabrizio
Ricciardi, Serena
De Toma, Alessandro
Friedlaender, Alex
Petrelli, Fausto
Addeo, Alfredo
Porzio, Giampiero
Ficorella, Corrado
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[38] Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression
Tambo, Yuichi
Sone, Takashi
Shibata, Kazuhiko
Nishi, Kouichi
Shirasaki, Hiroki
Yoneda, Taro
Araya, Tomoyuki
Kase, Kazumasa
Nishikawa, Shingo
Kimura, Hideharu
Kasahara, Kazuo
CLINICAL LUNG CANCER, 2020, 21 (05) : E366 - E379
[39] First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 positive NSCLC: A Network Meta-Analysis of Randomized Trials
Doherty, M.
Delos Santos, S.
Rahmadian, A. Putri
Chan, K.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S465 - S466
[40] An Indirect Comparison of Pembrolizumab Monotherapy Versus Ipilimumab plus Nivolumab for First-Line Metastatic NSCLC with PD-L1 TPS≥1%
Halmos, B.
Burke, T.
Kalyvas, C.
Insinga, R.
Vandormael, K.
Frederickson, A.
Piperdi, B.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S23 - S24

← 1 2 3 4 5 →